期刊文献+

高变异药物硫酸氢氯吡格雷片的人体生物等效性及饮食影响 被引量:5

Bioequivalence of Highly Variable Drug Clopidogrel Bisulfate and Food Effects on Its Pharmacokinetics
原文传递
导出
摘要 目的评价空腹和餐后服用两种硫酸氢氯吡格雷片的生物等效性,考察饮食对氯吡格雷在中国人体内的药动学影响。方法针对氯吡格雷的高变异性,根据文献报道的该药的个体内变异系数等数据计算空腹给药试验所需受试者例数为70例;根据空腹试验的结果计算餐后给药生物等效性试验所需受试者例数为56例。两次试验分别采用健康男性受试者进行双周期双交叉(清洗期为7 d)单次口服受试制剂和参比制剂300 mg的试验方法。结果空腹口服受试制剂与参比制剂后,氯吡格雷的ρmax分别为(5.78±4.93)、(6.17±6.76)ng·mL-1,tmax分别为(0.71±0.33)、(0.76±0.40)h,AUC0-30 h分别为(8.83±6.72)、(9.35±7.93)ng·h·mL-1,相对生物利用度为(107.3±50.5)%;餐后口服受试制剂与参比制剂后,氯吡格雷的ρmax分别为(30.9±12.5)、(30.1±13.3)ng·mL-1,tmax分别为(1.9±0.6)、(1.9±0.6)h,AUC0-30h分别为(65.0±21.6)、(65.8±22.3)ng·h·mL-1,相对生物利用度为(102.0±23.1)%。两种硫酸氢氯吡格雷片之间在空腹和高脂餐给药后药动学参数均无显著差异(P>0.05)。结论对高变异药物氯吡格雷的生物等效性样本量设计合理。受试制剂和参比制剂在空腹给药和高脂餐后给药情况下均具有生物等效性。与空腹给药相比,高脂餐后给药,tmax延后1.2 h,ρmax和AUC0-30 h分别增大5倍和7倍左右。 OBJECTIVE To investigate the bioequivalence of clopidogrel bisulfate under fasting and fed conditions and the effect of food on the pharmacokinetics of clopidogrel in chinese volunteers. METHODS Based on the high variability of clopidogrel and its intra-subject variation coefficient data reported in the literatures, the sample size of the bioequivalence evaluation of clopidogrel tablets under fasting condition was estimated and designed to 70 subjects. Based on the fasting test results, the sample size of the bioequiva- lence evaluation of clopidogrel tablets in fed condition was designed to 56 subjects. Both of the studies were designed to the open, ran- domized and crossover tests in which a single oral dose of 300 mg clopidogrel bisulfate tablets was administered to healthy male volun- teers. RESULTS The pharmacokinetic parameters of clopidogrel in fasting condition for the test and reference tablets were as follows : ρmax (5.78±4. 93)vs. (6. 17±6. 76)ng·mL-' ,tmax (0. 71 ±0. 33 ) vs. (0. 76±0. 40) h, AUC0-3oh (8. 83 ± 6. 72) vs. (9. 35 ± 7.93 ) ng·h·mL^-1 , and the relative bioavailability of clopidogrel was ( 107.3 ± 50. 5 ) % ; the pharmacokinetic parameters for the test and reference tablets in fed state were as follows -'Pmax ( 30. 9 ± 12. 5 ) VS. ( 30. 1 ± 13. 3 )ng·mL- 1, tmax ( 1. 9 ± 0. 6 ) VS. ( 1. 9 ± 0. 6 ) h, AUCo-30 h ( 65. 0 ± 21. 6 ) VS. ( 65. 8 ± 22. 3 )ng · h · mL^- 1, and the relative bioavailability was ( 102. 0 ± 23. 1 ) %. There were no signif- icant differences in pharmaeokinetic parameters between two tablets ( P 〉 0. 05 ). CONCLUSION The sample size is reasonably de- signed for the bioequivalence of highly variable drug clopidogrel tablets. The test and reference tablets are considered bioequivalent in human. The pin, and AUC0-30 h increase 5-fold and 7-fold, and tind increase 1.2 h in fed condition compared to the fasting condition.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第16期1437-1441,共5页 Chinese Pharmaceutical Journal
关键词 高变异 样本量 氯吡格雷 生物等效性 饮食影响 液相二级质谱联用 highly variable sample size clopidogrel bioequivalence food effect LC-MS/MS
  • 相关文献

参考文献5

二级参考文献56

  • 1Mega JL,Close SL,Wiviott SD.Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,49(4):1083.
  • 2Holmes DJ,Gj D,Kaul S,et al.ACCF/AHA clopidogrel clinical alert:approaches to the FDA " boxed warning":a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association[J].Circulation,2010,122(5):537-557.
  • 3Terpening C.Clopidogrel:a pharmacogenomic perspective on its use in coronary artery disease[J].Clin Med Insights Cardiol,2010,4(4):117-128.
  • 4Verstuyft C,Simon T,Kim RB.Personalized medicine and antiplatelet therapy:ready for prime time[J]? Eur Heart J,2009,30(16):1943-1963.
  • 5Anderson CD,Biffi A,Greenberg SM,et al.Personalized approaches to clopidogrel therapy:are we there yet[J]? Stroke,2010,41(12):2997-3002.
  • 6CYP2C19 allele nomenclature.Home Page of the Human Cytochrome P450(CYP) Allele Nomenclature Committee[http://www.cypalleles.ki.se/cyp2c19.htm].Accessed 2011 Feb 15.
  • 7Shuldiner AR,O'connell JR,BlidenKP,et al.Association of cytochrome P4502C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849-857.
  • 8Sibbing D,Koch W,Gebhard D,et al.Cytochrome 2C19 * 17 allelic variant,platelet aggregation,bleeding events,and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J].Circulation,2010,121 (4):512-518.
  • 9Sibbing D,Stegherr J,Latz W,et al.Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J].Eur Heart J,2009,30(8):916-922.
  • 10Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovasculas events[J].N Engl J Med,2009,360(4):363-375.

共引文献68

同被引文献47

  • 1寇玲,傅思惟,刘建根,慕博,李淑梅.不同剂量盐酸替罗非班联合PCI治疗老年急性冠脉综合征合并糖尿病患者的有效性与安全性[J].中国老年学杂志,2014,34(3):579-581. 被引量:19
  • 2陈章强,洪浪,王洪,尹秋林,赖珩莉,邱赟.川芎嗪对急性冠脉综合征患者介入术后血小板活化及血管内皮功能的影响[J].中国中西医结合杂志,2007,27(12):1078-1081. 被引量:19
  • 3SHIMAMURA K, KIMURA S, ZHOU M, et al. Evidence for the involvement of the cyclooxygenase-metabolic pathway in diclofe-nac-induced inhibition of spontaneous contraction of rat portal vein smooth muscle cells [ J]. J Smooth Muscle Res, 2005, 41 (4) :195-206.
  • 4FORTUN P J, HAWKEY C J. Nonsteroidal antiinflanmlatory drugs and the small intestine[J]. Curr Opin Gastroenterol, 2005, 21 (2) : 169-75.
  • 5BOURLERT A. Dielofenac intramuscular single dose to decrease pain in post operative Caesarean section: A double blind randomized controlled trial [J]. J Med Assoc Thai, 2005,88(1 ) :15-19.
  • 6RIGATO H M, MORENO R A, ORPINELLI E Z, et al. A sim- ple high-performance liquid chromatographic method for the de- termination of diclofenac in human plasma : Application to a com- parative bioavailability study [ J ]. lnt J Clin Pharmacol Ther, 2009 ,47 (2):132-140.
  • 7YILMAZ B. GC-MS Determination of diclofenac in human plasma [J]. Chromatographia, 2010,71(5-6) :549-551.
  • 8GARCfA M D, GALERA M M, VALVERDE R S, et al. Col- umn switching liquid chromatography and post-column photo- chemically fluorescence detection to determine imidacloprid and 6-chloronicotinic acid in honeybees [ J]. J Chromatogr A, 2007, 1147( 1 ) : 17-23.
  • 9SACHSE J, KOLLER J, HERTFER S, et al. Automated analy- sis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection [J]. JChromatogrB ,2006,30 (2) :342-348.
  • 10SHEP D, OJHA A, PATEL S, et al. Pharmacokinetie profile of an intradeltoid dielofenae injection in obese Indian volunteers [J]. J Pain Res, 2010,19(3) :235-240.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部